Maria Xydia
Overview
Explore the profile of Maria Xydia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baldwin J, Heuser-Loy C, Saha T, Schelker R, Slavkovic-Lukic D, Strieder N, et al.
Cell
. 2024 Sep;
187(23):6614-6630.e21.
PMID: 39276774
Mitochondrial loss and dysfunction drive T cell exhaustion, representing major barriers to successful T cell-based immunotherapies. Here, we describe an innovative platform to supply exogenous mitochondria to T cells, overcoming...
2.
Sanna F, Benesova I, Pervan P, Krenz A, Wurzel A, Lohmayer R, et al.
Front Immunol
. 2024 Aug;
15:1437224.
PMID: 39211051
IL-32 expression is important for pathogen clearance but detrimental in chronic inflammation, autoimmunity, and cancer. T cells are major IL-32 producers in these diseases and key mediators of pathogen and...
3.
Hussein A, Stamova S, Xydia M, Beckhove P
Cancer Cell
. 2024 Jun;
42(6):938-941.
PMID: 38861930
Cancer immunotherapy is a pillar of clinical oncology but only achieves long-term remissions in a minority of cases. In this issue, van Elsas et al. show that effective immunotherapy requires...
4.
Menevse A, Ammer L, Vollmann-Zwerenz A, Kupczyk M, Lorenz J, Weidner L, et al.
Acta Neuropathol Commun
. 2023 May;
11(1):75.
PMID: 37158962
Glioblastoma (GB) IDH-wildtype is the most malignant primary brain tumor. It is particularly resistant to current immunotherapies. Translocator protein 18 kDa (TSPO) is upregulated in GB and correlates with malignancy...
5.
Sorrentino A, Menevse A, Michels T, Volpin V, Durst F, Sax J, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35606086
Background: Cancer immunotherapeutic strategies showed unprecedented results in the clinic. However, many patients do not respond to immuno-oncological treatments due to the occurrence of a plethora of immunological obstacles, including...
6.
Pinkert J, Boehm H, Trautwein M, Doecke W, Wessel F, Ge Y, et al.
Oncoimmunology
. 2022 Feb;
11(1):2008110.
PMID: 35141051
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), a cell surface receptor, is expressed on normal epithelial tissue and highly expressed in cancers of high unmet medical need, such as non-small...
7.
Xydia M, Rahbari R, Ruggiero E, Macaulay I, Tarabichi M, Lohmayer R, et al.
Nat Commun
. 2021 Feb;
12(1):1119.
PMID: 33602930
Regulatory CD4 T cells (Treg) prevent tumor clearance by conventional T cells (Tconv) comprising a major obstacle of cancer immune-surveillance. Hitherto, the mechanisms of Treg repertoire formation in human cancers...
8.
Ge Y, Bohm H, Rathinasamy A, Xydia M, Hu X, Pincha M, et al.
Cancer Immunol Res
. 2019 Nov;
7(12):1998-2012.
PMID: 31672785
Endogenous antitumor effector T-cell responses and immune-suppressive regulatory T cells (Treg) critically influence the prognosis of patients with cancer, yet many of the mechanisms of how this occurs remain unresolved....
9.
Xydia M, Ge Y, Quitsch U, Beckhove P
Immunol Cell Biol
. 2010 Dec;
89(6):670-80.
PMID: 21151195
Effector memory T cells (T(EM)) have an important role in immunity against infection. However, little is known about the factors regulating T(EM) maintenance and proliferation. In this study, we investigated...